Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges

Rishabh Mittal1, Nidhi Chourasia1, Vivek K Bharti1

  • 1Department of Biochemistry, AIIMS Bhopal, Bhopal, Madhya Pradesh, India.

Insights

Biomarkers like CRP, ferritin, and IL-6 can predict COVID-19 severity and prognosis. Early detection of disease progression and organ damage is crucial for prompt treatment.

Area of Science:

  • Biochemistry
  • Immunology
  • Pathology

Background:

  • High morbidity and mortality in COVID-19 necessitate early severity prediction.
  • Uncertainty in transmission modes and disease manifestation requires reliable biomarkers.

Purpose of the Study:

  • To review and identify key biomarkers for COVID-19 diagnosis, prognosis, and severity assessment.
  • To analyze biomarkers impacting organ-specific damage in COVID-19 patients.

Main Methods:

  • Systematic literature review of PubMed publications (2019-2021).
  • Analysis of biochemical, immune-inflammatory, nucleic acid, and cellular biomarkers.
  • Assessment of 65 biomarkers across five organs: lung, liver, cardiac, kidney, and neural.

Main Results:

  • Elevated CRP, TNF-α, ferritin, IL-6, D-dimer, Procalcitonin, and Fibrinogen to Albumin Ratio (FAR) are associated with COVID-19 severity.
  • Decreased platelet count, lymphocyte count, leukocyte count, and CD4+/CD8+ ratio correlate with disease progression and cytokine storm.
  • Aptamers show potential for COVID-19 diagnosis, possibly outperforming antibodies.

Conclusions:

  • Identified biomarkers offer promising tools for early COVID-19 diagnosis and prognosis.
  • Biomarker profiles correlate with organ-specific damage and cytokine storm, aiding severity prediction.
  • These biomarkers are vital for managing future COVID-19 waves and related pandemics.